Investment analysts at StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO - Get Free Report) in a report issued on Thursday. The brokerage set a "strong-buy" rating on the medical research company's stock.
Global Cord Blood Price Performance
CO stock remained flat at $1.25 during midday trading on Thursday. The company's stock had a trading volume of 51 shares, compared to its average volume of 216,519. The business has a 50-day moving average of $1.56 and a 200 day moving average of $1.40. Global Cord Blood has a 52 week low of $2.03 and a 52 week high of $5.50. The firm has a market capitalization of $151.94 million, a PE ratio of 1.95 and a beta of 0.16.
About Global Cord Blood
(
Get Free Report)
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
Featured Articles
Before you consider Global Cord Blood, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global Cord Blood wasn't on the list.
While Global Cord Blood currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
